Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial
In this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second-line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.
Authors
- Abrial Catherine
- Kwiatkowski Fabrice
- Judith Passildas (ORCID: https://orcid.org/0000-0002-3575-7260)
- Delecroix Valérie
- Nabholtz Jean‐Marc
- Bernadach Maureen
- Chollet Philippe
- Mouret‐Reynier Marie‐Ange
- Curé Hervé
- Pouget Mélanie
- Vanpraagh‐Doreau Isabelle
- Dubray‐Longeras Pascale
Institutions
- Inserm (FR)
- Université Clermont Auvergne (FR)
- Clinical Investigation Center Plurithematic Tours (FR)
- Sigma Clermont (FR)
- Centre Jean Perrin (FR)
- Institut Jean Godinot (FR)
- Clinique Mutualiste de l'Estuaire (FR)
- Imagerie Moléculaire et Stratégies Théranostiques
Publication Details
- Journal
- Health Science Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/hsr2.70052
- Citations
- 8
- Primary Topic
- Curcumin's Biomedical Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Ligue Contre le Cancer